Research from the University of Florida, Mayo Clinic, and Vanderbilt University, in collaboration with the Parkinson’s Progression Markers Initiative, suggests that molecular and imaging biomarkers provide distinct information about Parkinson’s disease.
UF startup Neuropacs™ Corp., a leader in AI‑powered neurodiagnostics, announced the publication of a seminal study co-authored by David Vaillancourt, PhD, the company’s Co‑Founder and Chief Scientific Officer. The research published in Annals of Neurology reveals a positive alpha-synuclein (α-synuclein) seed amplification assay (SAA) and the automated imaging differentiation for parkinsonism (AIDP) provide unique information key to understanding Parkinson’s disease (PD). The Neuropacs™ software using the AIDP was granted de novo classification by the FDA, clearing the way for clinical use.
